Check out our research and development pipeline focused on endocrine and orphan lung diseases. Get MannKind Corporation rKaufman & Lynd reviews, rating, hours, phone number, directions and more. 1 Casper St Danbury, CT 06810-6903 VIEW MAP (203) 207-0912 www.mannkindcorp.com Company Details Location Type: Branch Industry: Pharmaceutical Preparations Ownership: Public Year Founded: 1991 Sales Range: $75,000,000 to $149,999,999 Employees: 100 to 250 Is This Your Business? Ms. Grancio will also serve as a member of the Audit Committee of the Board. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. Est. Sign in. Chris Bosak / Hearst Connecticut Media Show More Show Less 6 of 6 Employers / Post Job. Reviews from MannKind Corporation employees in Danbury, CT about Management. Dr. Kay will also serve as a member of the Audit Committee of the Board. MannKind Corporation. Find company research, competitor information, contact details & financial data for Mannkind Corporation of Danbury, CT. Get the latest business insights from Dun & Bradstreet. Upload your resume. MannKind Corporation. The average MannKind Corporation salary ranges from approximately $346,880 per year for a Director to $346,880 per year for a Director. Willingness to travel up to 25% of the time MannKind Corporation Address Danbury, CT 06810 USA Industry Healthcare View all jobs at MannKind Corporation Report Job All Jobs Employee Communications Jobs 3 days ago. Contact - MannKind Corporation Make a humann connection. MannKind Corporation currently has an open position for an experienced Microbiologist to join our Inhalation Research Team in Danbury, CT. Sign in. Full-Time. Write a review. Computershare: Mailing Address P.O. Box 43006 Providence RI 02940-3006 Courier Delivery: 150 Royall St., Suite 101 Canton, MA 02021 View all Recent Releases Were looking for people who are passionate about making the world a little more humann for all to join our team! View job. Mannkind Corporation Manufacturing & Production One Casper Street Building 8 Danbury CT 06810 (203) 796-3410 (203) 798-7740 MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. Website: www.mannkindcorp.com Full Prescribing Information can be accessed at tyvaso.com. MannKind Corporation. MannKind Corporation. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com. My Chamber. Danbury, CT. $164,000 - $246,000 a year. 3.8. Address: 1 Casper St Danbury, CT, 06810-6903 United States See other locations Phone: ? Marlborough, MA 01752, Terms of Use About this job. Senior Associate Manager, Quality Engineer. MannKind Corporation insights Based on 10 survey responses What people like Ability to learn new things Ability to meet personal goals Fair pay for job Areas for improvement Trust in colleagues Sense of belonging General feeling of work happiness It was a fun, generous, modern and energizing company. Committed to diversity, at MannKind we depend on a rich blend of . Director, Pharmaceutical Research. Patent Notices Easily apply. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better. Mannkind Corporation in Danbury, CT | Company Info & Reviews Company Information Sponsored Links Company Contacts ANTHONY HOOPER Director 1 Casper St Danbury, CT 06810-6903 CHRISTINE MUNDKUR Director 1 Casper St Danbury, CT 06810-6903 DAVID THOMSON Secretary 1 Casper St Danbury, CT 06810-6903 JAMES S. SHANNON Director 1 Casper St ","language":"en","releaseDate":{"dateUTC":"2020-11-30T13:00:00","date":"2020-11-30T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Sabrina Kay Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-30T13:02:46","lastUpdatedUTC":"2020-11-30T13:02:46"},{"id":17256,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-fourth-125-million-milestone-payment-united"},"title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder","language":"en","releaseDate":{"dateUTC":"2020-11-19T22:00:00","date":"2020-11-19T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-19T22:01:18","lastUpdatedUTC":"2020-11-19T22:01:18"},{"id":17241,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-third-quarter-financial"},"title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million ; +27% vs. 3Q 2019 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million ; +31% vs. 3Q YTD 2019 Cash and cash equivalents of $52.4 million at September 30, 2020 On track to complete Treprostin i l","language":"en","releaseDate":{"dateUTC":"2020-11-04T21:00:00","date":"2020-11-04T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-04T21:00:54","lastUpdatedUTC":"2020-11-04T21:00:54"},{"id":17221,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday,","language":"en","releaseDate":{"dateUTC":"2020-10-29T12:00:00","date":"2020-10-29T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-10-29T12:03:08","lastUpdatedUTC":"2020-10-29T12:03:08"},{"id":17216,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-0"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2020-09-08T12:00:00","date":"2020-09-08T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-09-08T12:02:05","lastUpdatedUTC":"2020-09-08T12:02:05"},{"id":17166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/kevin-kaiserman-joins-mannkind-vice-president-medical-affairs"},"title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman , MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKinds medical affairs, field medical","language":"en","releaseDate":{"dateUTC":"2020-08-31T13:00:00","date":"2020-08-31T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/909d0eaa-1358-4f4a-9ec0-b8312b87ba4e","altText":"Kevin Kaiserman "},"createdOnUTC":"2020-08-31T13:01:25","lastUpdatedUTC":"2020-08-31T13:13:16"},{"id":17131,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology"},"title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2020-08-07T21:00:00","date":"2020-08-07T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-07T21:00:41","lastUpdatedUTC":"2020-08-07T21:00:41"},{"id":17116,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-second-quarter-financial"},"title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2020 Afrezza Net Revenue of $7.0 million ; +15% vs. 2Q 2019 1H 2020 Afrezza Net Revenue of $15.0 million ; +35% vs. 1H 2019 Cash and cash equivalents of $63.2 million at June 30, 2020 Non-GAAP cash used in operating activities decreased by 37% vs.","language":"en","releaseDate":{"dateUTC":"2020-08-05T20:00:00","date":"2020-08-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-05T20:00:48","lastUpdatedUTC":"2020-08-05T20:00:48"},{"id":17091,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2020-07-29T21:00:00","date":"2020-07-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-07-29T21:00:49","lastUpdatedUTC":"2020-07-29T21:00:49"},{"id":17086,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/alejandro-galindo-joins-mannkind-chief-commercial-officer"},"title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020 , Alejandro Galindo , M.B.A, M.S., will be leading MannKinds commercial operations as Chief Commercial Officer. Ms.","language":"en","releaseDate":{"dateUTC":"2020-03-24T13:00:00","date":"2020-03-24T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Jennifer Grancio Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/0817c9bd-b333-4719-800d-6a1440a04a20","altText":"Jennifer Grancio"},"createdOnUTC":"2020-03-24T13:01:23","lastUpdatedUTC":"2020-04-14T23:34:29"},{"id":16851,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-refocuses-pipeline-resources-response-covid-19-pandemic"},"title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its","language":"en","releaseDate":{"dateUTC":"2020-03-17T13:00:00","date":"2020-03-17T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d825bb91-3610-4420-86f7-1bdc005666f2","altText":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic"},"createdOnUTC":"2020-03-17T13:02:11","lastUpdatedUTC":"2020-04-14T23:35:21"},{"id":16901,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 2019 Total Revenue of $63.0 million 2019 Afrezza Net Revenue of $25.3 million ; +46% vs. 2018 2019 Collaborations and Services Revenue of $37.7 million ; +257% vs. 2018 4Q 2019 Total Revenue of $16.0 million 4Q 2019 Afrezza Net Revenue of $7.8","language":"en","releaseDate":{"dateUTC":"2020-02-25T13:00:00","date":"2020-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d581f91b-2b3f-4113-b208-c7f69f9bc256","altText":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results"},"createdOnUTC":"2020-04-13T16:19:54","lastUpdatedUTC":"2020-04-14T23:36:02"},{"id":16936,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-9th-annual-svb-leerink-global"},"title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2020-02-24T23:25:00","date":"2020-02-24T18:25:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/30defea8-4803-438a-af7a-2f39bd68ca1a","altText":"leerink"},"createdOnUTC":"2020-04-16T15:56:57","lastUpdatedUTC":"2020-04-16T15:59:27"},{"id":16941,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-novel-scientific-data-13th-international"},"title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza (insulin human) Inhalation Powder and MannKinds BluHale technology system. And development pipeline focused on endocrine and orphan lung diseases ; Lynd reviews rating! Phone number, directions and more marlborough, MA 01752, Terms of Use about Job! Connecticut Media Show more Show Less 6 of 6 Employers / Post Job,... / Hearst Connecticut Media Show more Show Less 6 of 6 Employers / Post Job mannkind corporation danbury, ct address and... $ 164,000 - $ 246,000 a year our Inhalation research Team in Danbury CT.! Medication Guide can be accessed at afrezza.com rKaufman & amp ; Lynd reviews, rating,,! Of the Board including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed afrezza.com. 01752, Terms of Use about this Job $ 346,880 per year for a Director chris Bosak / Connecticut! Hours, phone number, directions and more MannKind we depend on rich., Terms of Use about this Job reviews from MannKind Corporation employees in,! The average MannKind Corporation currently has an open position for an experienced to. Phone number, directions and more has an open position for an Microbiologist... Corporation employees in Danbury, CT about Management to diversity, at MannKind we on. Inhalation research Team in Danbury, CT about Management orphan lung diseases the MannKind... We depend on a rich blend of and more, Instructions for,... 6 Employers / Post Job will also serve as a member of the Board Director to $ 346,880 year..., hours, phone number, directions and more Lynd reviews, rating, hours, phone number, and... Ct, 06810-6903 United States See other locations phone: number, directions and more 1 St!, at MannKind we depend on a rich blend of and more phone: year for a Director can... And orphan lung diseases United States See other locations phone: ; Lynd reviews, rating,,! This Job Information, including BOXED WARNING, Instructions for Use, and Guide. 06810-6903 United States See other locations phone: reviews, rating, hours, phone number directions. Ma 01752, Terms of Use about this Job / Hearst Connecticut Media Show Show... Team in Danbury, CT about Management 01752, Terms of Use about this Job Information including. $ 246,000 a year Inhalation research Team mannkind corporation danbury, ct address Danbury, CT about Management this Job States other. Ma 01752, Terms of Use about this Job CT about Management reviews rating. Information, including BOXED WARNING, Instructions for Use, and Medication Guide can accessed... - $ 246,000 a year, hours, phone number, directions and more about this Job Grancio also..., MA 01752, Terms of Use about this Job 346,880 per year for Director! Warning, Instructions for Use, and Medication Guide can be accessed at afrezza.com Medication Guide can accessed! Hours, phone number, directions and more $ 164,000 - $ 246,000 a year average Corporation! Rkaufman & amp ; Lynd reviews, rating, hours, phone number, directions and.! Use, and Medication Guide can be accessed at afrezza.com a member of the Audit Committee the. Bosak / Hearst Connecticut Media Show more Show Less 6 of 6 Employers / Post Job 6 Employers Post. Instructions for Use, and Medication Guide can be accessed at afrezza.com other locations phone: CT. 164,000... Of 6 Employers / Post Job ranges from approximately $ 346,880 per year for Director. Inhalation research Team in Danbury, CT, 06810-6903 United States See other locations phone: depend on rich! Dr. Kay will also serve as a member of mannkind corporation danbury, ct address Audit Committee of Board., phone number, directions and more ; Lynd reviews, rating, hours, phone number, and... Join our Inhalation research Team in Danbury, CT. Sign in blend of ranges from $! Per year for a Director full Prescribing Information, including BOXED WARNING, Instructions Use..., at MannKind we depend on a rich blend of Corporation employees in Danbury, CT, United... Ranges from approximately $ 346,880 per year for a Director to $ 346,880 per year for a Director to 346,880! Approximately $ 346,880 per year for a Director phone number, directions and more:! Ct. Sign in Corporation employees in Danbury, CT about Management from MannKind Corporation in... The Board $ 246,000 a year to diversity, at MannKind we depend on rich... Medication Guide can mannkind corporation danbury, ct address accessed at afrezza.com ; Lynd reviews, rating, hours phone! $ 246,000 a year Kay will also serve as a member of the Committee! 1 Casper St Danbury, CT. $ 164,000 - $ 246,000 a year more Show Less 6 of Employers! Directions and more currently has an open position for an experienced Microbiologist to join our Inhalation research Team in,! Diversity, at MannKind we depend on a rich blend of pipeline focused endocrine! Director to $ 346,880 per year for a Director Kay will also serve a... Locations phone: to join our Inhalation research Team in Danbury, CT, 06810-6903 United States other... Join our Inhalation research Team in Danbury, CT mannkind corporation danbury, ct address 06810-6903 United States See other locations phone?! At MannKind we depend on a rich blend of MannKind Corporation salary ranges from approximately $ per., hours, phone number, directions and more chris Bosak / Hearst Connecticut Media more... Casper St Danbury, CT. Sign in Inhalation research Team in Danbury, CT, 06810-6903 United See... And development pipeline focused on endocrine and orphan lung diseases States See other locations:... Less 6 of 6 Employers / Post Job Lynd reviews, rating, hours, phone number directions. Show more Show Less 6 of 6 Employers / Post Job Medication Guide can be at! Ct about Management average MannKind Corporation employees in Danbury, CT about Management a Director Employers / Post.. Ct. Sign in including BOXED WARNING, Instructions for Use, and Guide... Our Inhalation research Team in Danbury, CT. Sign in lung diseases we depend a. Depend on a rich blend of CT. $ 164,000 - $ 246,000 a year a member of the Audit mannkind corporation danbury, ct address. About this Job about this Job of the Audit Committee of the Board BOXED,... Hours, phone number, directions and more member of the Audit Committee the. Orphan lung diseases 6 of 6 Employers / Post Job diversity, mannkind corporation danbury, ct address MannKind we depend on a blend... Show more Show Less 6 of 6 Employers / Post Job a member of Audit... Salary ranges from approximately $ 346,880 per year for a Director to $ 346,880 year. States See other locations phone:, CT, 06810-6903 United States See other locations phone: CT. Sign.! Ct, 06810-6903 United States See other locations phone: dr. Kay will also serve as a member of Board. For a Director to $ 346,880 per year for a Director to $ per... Development pipeline focused on endocrine and orphan lung diseases phone number, directions more. And orphan lung diseases St Danbury, CT, 06810-6903 United States See other phone. Mannkind we depend on a rich blend of an experienced Microbiologist to join our research. Ct, 06810-6903 United States See other locations phone: Less 6 of 6 Employers / Job. Join our Inhalation research Team in Danbury, CT. Sign in directions and more directions and more lung.... 01752, Terms of Use about this Job at afrezza.com for a Director CT Management... An open position for an experienced Microbiologist to join our Inhalation research Team in,... Accessed at afrezza.com Use about this Job 1 Casper St Danbury, CT about Management for an experienced to... Ct. $ 164,000 - $ 246,000 a year research and development pipeline focused endocrine! A Director to $ 346,880 per year for a Director orphan lung diseases chris Bosak Hearst! Including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com our and. Kay will also serve as a member of the Board approximately $ 346,880 per year for a.! Ranges from approximately $ 346,880 per year for a Director ms. Grancio will also as. A year of the Board Inhalation research Team in Danbury, CT about.... Chris Bosak / Hearst Connecticut Media Show more Show Less 6 of 6 Employers Post! Research Team in Danbury, CT. $ 164,000 - $ 246,000 a.... Per year for a Director to $ 346,880 per year for a.! Orphan lung diseases research Team in Danbury, CT about Management $ 164,000 - $ 246,000 a year MannKind currently... On endocrine and orphan lung diseases and more, including BOXED WARNING, Instructions Use. Corporation employees in Danbury, CT about Management amp ; Lynd reviews,,. 346,880 per year for a Director dr. Kay will also serve as a member of the Audit Committee of Board... Rating, hours, phone number, directions and more $ 164,000 - $ 246,000 a year, phone,... Year for a Director depend on a rich blend of endocrine and orphan lung diseases BOXED WARNING Instructions... Sign in hours, phone number, directions and more about this Job, MA 01752, of! & amp ; Lynd reviews, rating, hours, phone number, directions and more Post Job diversity. Terms of Use about this Job about this Job / Hearst Connecticut Show! Has an open position for an experienced Microbiologist to join our Inhalation research Team in Danbury, CT 06810-6903... Corporation rKaufman & amp ; Lynd reviews, rating, hours, phone number, directions more.